Hidrocortizon Zentiva (Hydrocortisone Hydrogen Succinate)

Hydrocortizon Zentiva is indicated for several serious medical situations where rapid glucocorticoid replacement or anti‑inflammatory action is required.

• Management of adrenal insufficiency, including adrenal crisis.
• Treatment of severe allergic reactions such as anaphylaxis.
• Control of acute inflammatory states like severe asthma exacerbations.
• Supportive therapy in shock or septic states where cortisol levels are inadequate.
• Adjunctive therapy for certain severe dermatologic or rheumatologic emergencies when intravenous glucocorticoid is preferred.

• Hydrocortizon Zentiva delivers hydrocortisone hydrogen succinate directly into the bloodstream, where it diffuses into cells and binds intracellular glucocorticoid receptors. The receptor‑ligand complex translocates to the nucleus and interacts with glucocorticoid response elements on DNA, modulating transcription of anti‑inflammatory proteins and suppressing pro‑inflammatory cytokine production. This genomic effect reduces edema, leukocyte migration, and immune activation, providing rapid systemic glucocorticoid activity.

Adverse reactions to Hydrocortizon Zentiva may vary in frequency and severity.

Common

• Transient hyperglycemia.
• Mild electrolyte disturbances (e.g., sodium loss, potassium retention).
• Injection‑site irritation or pain.
• Temporary mood changes such as anxiety or insomnia.
• Nausea or vomiting.
• Headache.

Serious

• Severe hypersensitivity reactions, including anaphylaxis.
• Acute adrenal suppression when therapy is stopped abruptly.
• Significant fluid retention causing hypertension or peripheral edema.
• Increased susceptibility to bacterial, viral, or fungal infections.
• Thromboembolic events such as deep‑vein thrombosis.

When prescribing Hydrocortizon Zentiva, clinicians should consider several precautionary measures to minimize risk.

• Assess baseline cortisol levels and adrenal function before initiating therapy.
• Use the lowest effective dose for the shortest duration necessary.
• Monitor blood glucose, electrolytes, and blood pressure regularly during treatment.
• Exercise caution in patients with uncontrolled diabetes, hypertension, or active infections.
• Avoid abrupt discontinuation; taper the dose gradually to prevent adrenal insufficiency.
• Consider potential fluid overload in patients with heart failure or renal impairment.
• Evaluate for psychiatric symptoms, especially in individuals with a history of mood disorders.

Hydrocortizon Zentiva can interact with other medicines, influencing its efficacy or safety profile.

Avoid

• Concurrent use of potent CYP3A4 inducers that may reduce glucocorticoid levels (e.g., rifampin, carbamazepine).
• Simultaneous administration of other systemic corticosteroids without medical justification.

Use with caution

• Antidiabetic agents, as glucocorticoids may increase blood glucose.
• Antihypertensive drugs, because fluid retention can counteract blood‑pressure control.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs), which may increase the risk of gastrointestinal ulceration.
• Immunosuppressants or biologic agents, due to additive infection risk.
• Vaccines, particularly live attenuated vaccines, because immune response may be blunted.